On June 20, 2024, Regeneron Pharmaceuticals, Inc announced that it held its annual general meeting on June 14, 2024, and declared voting results. Accordingly, the shareholder proposal submitted by John Chevedden requesting simple majority voting requirements was approved.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,069 USD | -0.19% |
|
+2.89% | +21.73% |
Jun. 26 | FDA approves Verona Pharma's therapy for 'smoker's lungs' | RE |
Jun. 26 | Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.73% | 116B | |
+16.49% | 122B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B | |
+122.59% | 11.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Declaration of Voting Results by Regeneron Pharmaceuticals, Inc